Related Experiment Video
Updated: Aug 25, 2026
Direct Infusion Device for Molecule Delivery in Plants
Published on: June 2, 2023
Effects of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies
Allan J Paul1, Douglas E Hutchens, Lawrence D Firkins
1Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802, USA.
Objective:
To evaluate the safety of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies at dose rates of 3 to 5 times the proposed maximum therapeutic dose.
Animals:
15 Collies (5 males and 10 females) that were confirmed as ivermectin-sensitive dogs.
Procedure:
Dogs were assigned to 3 treatment groups (control, 3X, or 5X group) in a randomized block design on the basis of the maximal ivermectin-sensitivity score obtained during preliminary screening. Dogs in groups 3X and 5X were treated at 3 and 5 times the maximum label dose, respectively. Control dogs received an application of an equal volume of a nonmedicated solution. Observation and scoring on all days were conducted to specifically include neurologic signs typical of ivermectin toxicosis, including lethargy, ataxia, abnormal mydriasis, and abnormal salivation.
Results:
None of the dogs had clinical abnormalities during the study period.
Conclusions And Clinical Relevance:
Analysis of results of this study indicates that dermal application of 10.0% imidacloprid-0.08% ivermectin is safe for use in ivermectin-sensitive Collies at dose rates of 3 or 5 times the proposed maximum therapeutic dose.
